The FDA has approved Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) oral pellets for children with venous thromboembolism between 3 months and under 12 years old. The indication stipulates that children receiving Pradaxa have received prior treatment with an injectable blood thinner given by injection for at least five days. FDA has also approved Pradaxa in capsule…